The abstract of a newly published study on the use of the Mediterranean diet (MD) by men on active surveillance (AS) for management of low-risk, localized prostate cancer states that … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, low risk, Mediterranean, surveillance | 4 Comments »
At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, intermediate risk, low risk, Provenge, ProVent, sipuleucel-T, surveillance, trial | Leave a comment »
One of the questions that has been nagging at Howard Wolinsky for a while now is whether he really needs to have another biopsy … ever! … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: active surveillance, biopsy, low risk, monitoring, Wolinsky | 8 Comments »
Last year, the American Society of Radiation Oncologists (ASTRO) looked at the available evidence comparing hypofractionated radiotherapy (either 60 Gy in 20 treatments or 70 Gy in 28 treatments) to standard fractionation (78 to 82 Gy in 40 to 44 treatments), and found it was at least as good in terms of oncological outcomes and toxicity. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: body, intermediate risk, low risk, radiation, SBRT, stereotactic | 1 Comment »
Some data presented a few weeks ago at the annual meeting of the European Association for Urology appear to have surprised not only the study’s authors, but pretty much everyone else as well. … READ MORE …
Filed under: Uncategorized | Tagged: low risk, replacement, serum, surgery, testosterone, TRT | 6 Comments »
An important new paper in the Journal of Vascular and Interventional Radiology has just provided us with the first large set of data on the outcomes of men with prostate cancer treated with focal laser ablation (FLA). … READ MORE …
Filed under: Uncategorized | Tagged: ablation, focal, intermediate risk, laser, localized, low risk | 5 Comments »
A research letter in the Journal of the American Medical Association reports a major uptake in the application of active surveillance as a first-line form of management of prostate cancer across the Veterans Affairs health system here in the US since 2005. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, Affairs, low risk, Management, surveillance, veterans | Leave a comment »
One paper to be presented at the upcoming annual meeting of the American Urological Association (AUS) gives results from treatment with a 3-month dose of androgen deprivation therapy (ADT) for men with low-risk prostate cancer compared to standard active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: ac tive, ADT, leuprolide, low risk, outcome, short-term, surveillance, trial | 9 Comments »
Another new media report (based on data just published in Lancet Oncology) states that “vascular-targeted photodynamic therapy” or VTP in combination with an experimental drug called padeliporfin or WST11 can be used to successfully treat low-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: laser, light, low risk, padeliporfin, photodynamic, therapy, TOOKAD, vascular, VTP, WST11 | 7 Comments »
Data from a recent paper in European Urology has further confirmed the value of active surveillance as a first-line management option for men diagnosed with low-risk prostate cancer. It has also confirm recent guidance for when men on active surveillance actually need to be advised that treatment is probably wise. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surveillance, first line, low risk, Management, PRIAS | 2 Comments »
A key question for men diagnosed with low-risk prostate cancer is always going to be whether, and for how long, they can defer treatment without increasing the risk that delayed treatment will be less effective (or riskier) in some ways. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: deferred, Diagnosis, immediate, low risk, surgery | 3 Comments »
A personal story on the MedPage Today web site this week tells a tale of how one 63-year-old professional journalist trod his own journey to management of his low-risk prostate cancer on active surveillance back in 2010. It may be instructive for many other patients newly diagnosed with low- and very low-risk prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, low risk, surveillance | Leave a comment »
In a new article in the journal Cancer, a research group associated primarily with the University of California, Los Angeles, have provided detailed information on the costs of first-line management of low-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: cost, low risk, Management, Treatment | 9 Comments »
A new article by Maurice et al. in the Canadian Urological Association Journal provides detailed information about the use of initial observation as a management strategy for low-risk prostate cancer between 2004 and 2011. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: active surveillance, low risk, Management, observation, watchful waiting | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 